Trial reportJournal of psychiatric research2018
Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial.
Trial report in Journal of psychiatric research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prolonging Remission in Depressed Elderly (PRIDE)
Efficacy of Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy in Remission of Suicidal Ideation
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Longitudinal Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Pharmacotherapy in Major Depressive Disorder in Older Adults: Phase 2 of the PRIDE Study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2022Trial
- Electroconvulsive Therapy (ECT) and Repetitive Transcranial Magnetic Stimulation (rTMS), Benefits and Adverse Effects in Patients with Depression: A Scoping Review.Journal of clinical medicine · 2026Review
- Neural mechanisms and neuromodulation therapies for non-suicidal self-injury.Molecular psychiatry · 2025Review
- Neurobiological Mechanisms of Electroconvulsive Therapy: Molecular Perspectives of Brain Stimulation.International journal of molecular sciences · 2025Review
- CB1 receptor mediates anesthetic drug ketamine‑induced neuroprotection against glutamate in HT22 cells.Experimental and therapeutic medicine · 2024Article
- Biological factors influencing depression in later life: role of aging processes and treatment implications.Translational psychiatry · 2023Review
- Japanese Project for Telepsychiatry Evaluation during COVID-19: Treatment Comparison Trial (J-PROTECT): Rationale, design, and methodology.Contemporary clinical trials · 2021Article
- Molecular Biomarkers of Electroconvulsive Therapy Effects and Clinical Response: Understanding the Present to Shape the Future.Brain sciences · 2021Review
- Long-term quality of life in treatment-resistant depression after electroconvulsive therapy.Journal of affective disorders · 2021Observational
- Article
- Mental Component Score (MCS) from Health-Related Quality of Life Predicts Incidence of Dementia in U.S. Males.The journal of prevention of Alzheimer's disease · 2021Article
- Risk Assessment of Electroconvulsive Therapy in Clinical Routine: A 3-Year Analysis of Life-Threatening Events in More Than 3,000 Treatment Sessions.Frontiers in psychology · 2021Article
- Double-Blinded Randomized Pilot Clinical Trial Comparing Cognitive Side Effects of Standard Ultra-Brief Right Unilateral ECT to 0.5 A Low Amplitude Seizure Therapy (LAP-ST).Brain sciences · 2020Article
- Electroconvulsive Therapy in Depression: Improvement in Quality of Life Depending on Age and Sex.The journal of ECT · 2020Article
- The innate immune system and neurogenesis as modulating mechanisms of electroconvulsive therapy in pre-clinical studies.Journal of psychopharmacology (Oxford, England) · 2020Review
- Increased Risk of Pain after Electroconvulsive Therapy among Depressed Patients: a Nationwide Study in Taiwan.The Psychiatric quarterly · 2020Article
- Effects of Electroconvulsive Therapy on Depression and Its Potential Mechanism.Frontiers in psychology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 11 institutions in 1 country.
Funding
Abstract
We examined whether electroconvulsive therapy (ECT) plus medications ("STABLE + PHARM" group) had superior HRQOL compared with medications alone ("PHARM" group) as continuation strategy after successful acute right unilateral ECT for major depressive disorder (MDD). We hypothesized that scores from the Medical Outcomes Study Short Form-36 (SF-36) would be higher during continuation treatment in the "STABLE + PHARM" group versus the "PHARM" group. The overall study design was called "Prolonging Remission in Depressed Elderly" (PRIDE). Remitters to the acute course of ECT were re-consented to enter a 6 month RCT of "STABLE + PHARM" versus "PHARM". Measures of depressive symptoms and cognitive function were completed by blind raters; SF-36 measurements were patient self-report every 4 weeks. Participants were 120 patients >60 years old. Patients with dementia, schizophrenia, bipolar disorder, or substance abuse were excluded. The "PHARM" group received venlafaxine and lithium. The "STABLE + PHARM" received the same medications, plus 4 weekly outpatient ECT sessions, with additional ECT session as needed. Participants were mostly female (61.7%) with a mean age of 70.5 ± 7.2 years. "STABLE + PHARM" patients received 4.5 ± 2.5 ECT sessions during Phase 2. "STABLE + PHARM" group had 7 point advantage (3.5-10.4, 95% CI) for Physical Component Score of SF-36 (P < 0.0001), and 8.2 point advantage (4.2-12.2, 95% CI) for Mental Component Score (P < 0.0001). Additional ECT resulted in overall net health benefit. Consideration should be given to administration of additional ECT to prevent relapse during the continuation phase of treatment of MDD. CLINICAL TRIALS.GOV: NCT01028508.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.